Lawrence Karsh, MD, FACS

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Astellas
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Bayer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Bristol Myers Squibb
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Janssen
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Dendreon
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Astra-Zeneca
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    QED
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Genomic Health
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    ABBVIE
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    UroGPO
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer